Acquisition by Valerie Morisset of 17847 shares of Eliem Therapeutics at 2.0E-4 subject to Rule 16b-3

Read at macroaxis.com

Published over six months ago View all stories for Eliem Therapeutics | Eliem Therapeutics Hype Analysis

Acquisition of 17847 common stock at 2.0E-4 of Eliem Therapeutics by Valerie Morisset on 8th of April 2024. This event was filed by Eliem Therapeutics with SEC on 2024-04-05. Statement of changes in beneficial ownership - SEC Form 4

We analyze Eliem Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eliem Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eliem Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eliem Therapeutics stock to make a market-neutral strategy. Peer analysis of Eliem Therapeutics could also be used in its relative valuation, which is a method of valuing Eliem Therapeutics by comparing valuation metrics with similar companies.

Check out Eliem Therapeutics Hype Analysis, Eliem Therapeutics Correlation and Eliem Therapeutics Performance. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.